A programme for long-term retention studies of C-14-labelled compounds in man using the Lund AMS facility

Organic compounds labelled with C-14 are routinely and widely used in clinical medicine and biomedical research. There are, however, considerable uncertainties in the current estimates of the absorbed doses to the body from C-14-labelled radiopharmaceuticals. In this paper a project is described using accelerator mass spectrometry (AMS) to perform investigations of the long-term biokinetics of C-14 from various C-14-labelled pharmaceuticals in man. The use of the AMS technique makes it possible to follow the turnover of the radionuclide administered for extensive periods and also to decrease the activity administered.